Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pre-treatment Predictor of Major Molecular Response Achievement in CML Patients

Esposito N.;Quintarelli C.;Colavita I.;Izzo B.;Peluso A.L.;Ruoppolo M.;Del Vecchio L.;Russo D.;Branford S.;Iacobucci I.;Thornquist M.;Barnett M.;Melo J.;Saglio G.;Radich J.;Perter L.;Martinelli G.;Kalebic T.;Hughes T.P.;Pane F.

2009-01-01